Trade Summary

3 days ago, Zalevsky Jonathan, serving as Chief R&D Officer at NEKTAR THERAPEUTICS (NKTR), sold 5,538 shares at $60.71 per share, for a total transaction value of $336,211.98. Following this transaction, Zalevsky Jonathan now holds 15,437 shares of NKTR.

This sale represents a 26.40% decrease in Zalevsky Jonathan's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, June 15, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, June 17, 2026 at 7:12 PM ET, 2 days after the trade was made.

NEKTAR THERAPEUTICS operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.